Translate
Roivant Sciences Ltd.
About
Roivant Sciences Ltd. — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
Apr 2 2026
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Apr 2 2026
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
Mar 28 2026
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
Mar 3 2026
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
Recent Videos
Roivant Sciences Expansion of Brepocitinib & Phase 3 Study Results for Batoclimab in TED | April 02
Apr 03, 2026
Roivant Sciences: Analyst Love & Legal Wins! #StockMarket #InvestmentInsights #LegalWins
Apr 01, 2026
Fri, Mar 20, 2026 🇯🇵 Roivant Sciences Insider Sold | ASIA Post-Market
Mar 21, 2026
Roivant Sciences Announces Genevant Sciences’ and Arbutus Biopharma’s $2 25 Billion Global Settlemen
Mar 04, 2026